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Abstract: Diabetes mellitus type 2 (DMT2) is a severe and
complex health problem. It is the most common type of
diabetes. DMT2 is a chronic metabolic disorder that affects
the way your body metabolizes sugar. With DMT2, your
body either resists the effects of insulin or does not
produce sufficient insulin to continue normal glucose
levels. DMT2 is a disease that requires a multifactorial
approach of controlling that includes lifestyle change and
pharmacotherapy. Less than ideal management increases
the risk of developing complications and comorbidities
such as cardiovascular disease and numerous social and
economic penalties. That is why the studies dedicated to
the pathophysiological mechanisms and the treatment of
DMT2 are extremely numerous and diverse. In this study,
exploratory data analysis approaches are applied for the
treatment of clinical and anthropometric readings of
patients with DMT2. Since multivariate statistics is a well-
known method for classification, modeling and inter-
pretation of large collections of data, the major aim of the
present study was to reveal latent relations between the
objects of the investigation (group of patients and control
group) and the variables describing the objects (clinical
and anthropometric parameters). In the proposed method
by the application of hierarchical cluster analysis and
principal component analysis it is possible to identify
reduced number of parameters which appear to be the
most significant discriminant parameters to distinguish
between four patterns of patients with DMT2. However,
there is still lack of multivariate statistical studies using
DMT2 data sets to assess different aspects of the problem
like optimal rapid monitoring of the patients or specific
separation of patients into patterns of similarity related to
their health status which could be of help in preparation
of data bases for DMT2 patients. The outcome from the
study could be of custom for the selection of significant
tests for rapid monitoring of patients and more detailed
approach to the health status of DMT2 patients.
Keywords: diabetes mellitus type 2, exploratory data
analysis, classification, PCA, CA, PLS-DA
1 Introduction
Diabetes mellitus represents a heterogeneous group of
metabolic diseases characterized by hyperglycemia re-
sulting from an inadequate insulin secretion or impaired
insulin effects [1]. More than 90% of all diabetic patients are
diagnosed with diabetes mellitus type 2 (DMT2) [2]. Insulin
resistance in muscle, liver and fat cells and relative insulin
deficiency due to beta-cell dysfunction are paramount for
the development of DMT2; however, other pathophysio-
logical mechanisms including impaired incretin effects,
increased glucagon secretion, increased kidney glucose
reabsorption and brain insulin resistance might also be of
great importance [3]. DMT2 is a chronic disease associated
with multiple complications, reduced quality of life,
premature mortality and large economic burden, most
directly affecting patients in low- and middle-income
countries [4,5]. According to a large multinational study,
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the prevalence of micro- and macrovascular complications
in patients with DMT2 was 53.5% and 27.2%, respectively,
while 38.4% of the diabetic individuals suffered from
diabetic neuropathy [6]. DMT2 and its complications were
negatively associated with patients’ quality of life in regard
to occupation, family and sexual life as well as future
perspectives [7]. The economic costs of diabetes have
increased by 26% from 2012 to 2017 in parallel with the
increased prevalence of diabetes and the increased cost per
person with diabetes [8,9].
Recently, the chemometrics and machine learning
methods were successfully applied to analyze metabolites
and to reveal the potential biomarkers in the clinical
diagnosis of DMT2. Free fatty acids were identified as
potential biomarkers of DMT2 by using heuristic evolving
latent projections, selective ion analysis and competitive
adaptive reweighted sampling [10]. Fisher linear discri-
minate analysis, support vector machine and decision tree
algorithms were employed to analyze elements in blood
samples, and it has been demonstrated that the level of
chromium and iron can serve as a valuable tool of
diagnosing DMT2 [11]. The support vector machine
approach was also applied to element concentration in
urine and hair samples to distinguish between DMT1 and
DMT2 [12]. By using orthogonal partial least-squares
discriminant analysis for metabolomic analysis of human
serum samples, it was revealed that metabolomics
fingerprints can identify potential biomarkers of red
meat consumption and can be related to the risk of
development of DMT2 [13]. The elemental analysis of
diabetic toenails and a large variety of machine learning
algorithms were combined for the non-invasive diagnosis
of DMT2, and it was found that the levels of aluminum,
cesium, nickel, vanadium and zinc in toenails can serve
as an indicator for the presence or absence of DMT2 [14].
The high incidence and costs as well as the predicted
increase of the diabetes prevalence in the future [15] justifies
the efforts to apply new multidisciplinary approaches in the
diabetic research. Therefore, the present study aims to
reveal hidden patterns and subgroups of diabetic patients
through hierarchical cluster analysis and principal compo-
nent analysis (PCA). The major goals of the present study
are as follows:
• proper classification of DMT2 patients and members of
control group;
• reduction of the number of variables for optimization
of the monitoring process of DMT2 patients;
• detection of patterns of similarity within the class of
DMT2 patients; and
• determination of discriminant parameters for each
identified pattern of patients.
2 Materials and methods
2.1 Input data and methods of exploratory
data analysis
2.1.1 Input data
Data subject to intelligent data analysis are collected from
patients’ records. Data were provided by the for active
treatment in endocrinology “Acad. Iv. Penchev”, Sofia,
Bulgaria and other endocrinological practices. Totally, 100
patients (57 females and 43 males) of age between 36 and 86
with duration of the disease between 1 and 30 years were
involved. Additionally, data for 20 healthy volunteers (11
females and 9 males) are added for comparison with the
same parameters tested. In Supplementary File 1: Table S1,
the clinical parameters measured and their code names are
indicated. The following parameters were taken into account:
• anthropometric data– age, duration of disease, weight,
height and body mass index (BMI)– calculated according
to the well-known formula: weight (kg)/height2 (m2),
waist and hip circumference;
• blood tests for thrombocytes, thrombocyte volume to
total volume and erythrocyte sedimentation rate;
• liver and muscle functional tests– alanine aminotrans-
ferase (ALAT), gamma glutamyl transferase (GGT), albumin
and creatinine phosphokinase (CPK);
• kidney function data – creatinine and uric acid;
• protein profile – total protein, lipid profile: high-density
lipoproteins (HDLs), low-density lipoproteins (LDLs),
very low-density lipoproteins (VLDLs), cholesterol and
triglycerides;
• electrolyte content – potassium ions and sodium ions;
• glucose levels (for patients checked in and checked out
during a session of medical treatment in a hospital) –
hemoglobin A1c, fasting glucose, postprandial glu-
cose, before sleep glucose and mean value of glucose.
2.2 Exploratory data analysis methods
In order to search for specific relationships between the
clinical parameters or between the DMT2 patients. The
input matrix has dimensions (120 × 35).
The following methods were used for data interpre-
tation.
2.2.1 Hierarchical cluster analysis
Hierarchical cluster analysis is used to detect groups of
similarity (clusters) between the objects of interest
1042  Miroslava Nedyalkova et al.
(DMT2 patients and control group) or between variables
(clinical parameters) by agglomerative hierarchical
clustering. The major steps in the analysis include data
normalization (z-standardization) to eliminate differ-
ences in the variable’s dimensions, squared Euclidean
distance as similarity measure, Ward’s method of
linkage, Sneath’s test of cluster significance and den-
drogram plot as a graphical output [16].
2.2.2 PCA
PCA is able to reduce the number of the variables
describing the system of objects in the direction of its
highest variance. New variables are introduced, and the
coordinates of the existing variable space are replaced
by new ones. These new coordinates are the so-called
latent factors or principal components (PCs). Their
correct interpretation is the main task since they carry
specific information about new types of relationships
within the original data set. Two sets of output results
are considered factor scores giving the new coordinates
of the factor space with the location of the objects and
factor loadings informing on the relationship between
the variables. Only statistically significant loadings
(>0.70) are taken into account for the interpretation.
The new PCs selected for interpretation should
explain a significant portion of the total variance of the
system. Usually, the first principal component (PC1)
explains the maximal part of the system variation and
each additional PC has a respective contribution to the
variance explanation but with less significance.
A reliable interpretation pattern requires normally
such a number of PCs, so that over 75% of the total
variation can be explained. Often, the Varimax rotated
PCA solution is applied that allows a better explanation
of the system since it strengthens the role of the latent
factors with higher impact on the variation explanation
and diminishes the role of PCs with lower impact [17].
2.2.3 Partial least square – discriminant analysis
(PLS-DA)
PLS-DA is a supervised linear classification method that
combines the properties of partial least squares (PLS)
regression with the discrimination power of a discrimi-
nant method. The PLS regression algorithm identifies
latent variables with a maximum covariance with the
classes [18], which are coded into a dummy matrix Y,
which represents the membership of each sample in a
binary form. The PLS2 model is then calibrated on the Y
matrix [19] and the probability that a sample belongs to
a specific class can be calculated on the basis of the
predicted responses [20]. Thus, each modeled class can
be described by a classification function reporting the
coefficients that determine the linear combination of the
original variables to define the classification score.
Before the PLS-DA calculation, data were auto scaled.
All calculation work was done by the use of the
software package STATISTICA 8.0 [21], except for the
classification PLS-DA models, which were calculated
with the MATLAB toolbox [22].
Ethical approval: All procedures were carried out in
accordance with the principles of ethics of the Declaration
of Helsinki. The Institutional Ethics Committee approved
the use of anonymous patients’ data for the study goals.
3 Results and discussion
3.1 Basic statistics
In Table 1, the basic statistical data for all 120 objects are
given.
Detailed statistical data about patients and control
group indicate that there are no significant differences
between the averages for both groups between indicators
such as age, thrombocytes, ALAT, total protein, albumin, K,
Na and the different cholesterol determinations (p < 0.05).
Statistically significant differences (p > 0.05) are observed
for BMI and the parameters related to it (weight, waist and
hip), GGT, CPK, creatinine, uric acid, triglycerides, erythro-
cyte sedimentation rate (ESR) and all glucose tests. All this
could be attributed to factors related to the disease not to
demographic reasons.
The correlation analysis carried out for the DMT2
group shows that statistically significant correlations
(p > 0.05) are found as follows:
Age: all parameters related to BMI (anthropometric
indicators), creatinine, uric acid, thrombocytes, Na and
HbA1c;
Duration: weight, ESR, ALAT, creatinine and uric acid;
Weight: all BMI indicators and Na;
Height: waist, ESR, ALAT and Na;
BMI: waist, hip, HDL and HbAc1;
Waist: hip, HDL and fast glucose;
Thrombocytes: ESR and total protein;
ESR: creatinine, albumin and HDL;
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ALAT: GGT, total protein, albumin and LDL;
GGT: uric acid, HDL, triglycerides, K, Na, postpran-
dial glucose and mean glucose 1;
Creatinine: uric acid and total protein;
Uric acid: VLDL and triglycerides;
Total protein: albumin, LDL and cholesterol;
Albumin: HDL, VLDL, HbA1c, before sleep glucose
and mean glucose 2;
HDL, LDL and VLDL: cholesterol and triglycerides;
Cholesterol: triglycerides, Na, fast glucose 1, mean
glucose 1, fast glucose 2 and mean glucose 2;
Triglycerides: Na, HbAc1, post prandial glucose and
mean glucose 1;
K: before sleep glucose 2 and mean glucose 2;
Na: HbAc1; and
For the control group very few significant correla-
tions are observed.
It could be concluded that several groups of mutual
correlated clinical parameters for DMT2 patients are
registered as follows:
• glucose test parameters;
• BMI and related anthropometric indicators;
• cholesterol indicators and triglycerides; and
• creatinine, uric acid and proteins.
This is important preliminary information about
links between the clinical and anthropometric indicators,
which could be of help for the multivariate statistical data
analysis.
3.1.1 Classification approach to separate controls from
DMT2 patients
The goal is to find specific descriptors able to distinguish
between the control group and the group of DMT2 patients.
The first approach used was hierarchical cluster
analysis. In Figure 1, the hierarchical dendrogram for
clustering of all 120 objects (20 of the control group and
100 DMT2 patients) is presented. The separation even in
this simple way of grouping is satisfactory– all members of
the control group are included in one single cluster. Only
one DMT2 patient is wrongly classified as member of the
control group. The most statistically significant descriptors
for the separation are all glucose test values, all anthropo-
metric indicators, ESR, GGT, CPK and cholesterol.
The same data set was treated by the PLS-DA
approach. In Figure 2, the separation of the objects
into two very different classes (N – control group and
P – patients with DMT2) is indicated. The discriminant
indicators are found to be as follows: postprandial
glucose test, almost all anthropometric parameters, age
and, surprisingly, potassium.
It is shown that reliable classification and separation
of the control group from the DMT2 patients’ group are
possible by the use of all clinical and anthropometric
parameters used. In the next steps of the multivariate
statistical analysis, an effort will be made to reduce the
number of parameters used to optimize the monitoring
of the patients.
3.1.2 Hierarchical cluster analysis of clinical parameters
In Figures 3 and 4, the hierarchical dendrograms for
clustering of the clinical parameters (normalized inputs,
squared Euclidean distances as similarity measure,
Table 1: Mean values and standard deviations for 34 clinical
parameters (variable “sex” is omitted)




Age 50.35 9.82 60.29 10.58
Duration 0.00 0.00 7.35 6.47
Weight 71.05 8.82 84.22 18.30
Height 173.60 7.71 165.70 10.38
BMI 22.90 1.94 30.87 6.02
Waist (W) 86.85 4.02 103.18 12.44
Hip (H) 88.60 6.46 109.65 14.20
W/H 0.98 0.05 0.95 0.07
Thromboc 276.95 48.16 256.10 72.41
Thrvol/Vol 0.26 0.04 0.22 0.07
ESR 16.35 6.53 23.84 21.51
ALAT 28.85 9.22 29.39 23.01
GGT 38.45 12.01 49.56 48.27
CPK 67.40 36.65 101.95 121.84
Creatinine 82.85 14.63 96.29 35.00
Uric acid 264.45 73.94 297.98 83.68
Total protein 70.01 6.20 70.68 5.26
Albumin 39.90 5.86 38.63 3.92
HDL 1.15 0.19 1.10 0.24
LDL 2.16 0.35 2.95 1.02
VLDL 0.76 0.40 0.86 0.41
Cholesterol 3.70 0.67 5.05 1.51
Triglycerides 1.17 0.40 2.54 3.29
K 4.08 0.61 4.61 0.52
Na 138.60 4.42 140.23 3.47
HbA1c 5.40 0.38 8.65 1.90
Fast glucose 1 4.73 0.57 9.78 3.78
Postprandial 4.91 0.58 10.70 3.90
Before sleep 4.80 0.40 10.30 4.64
Mean 1 4.83 0.45 10.09 3.37
Fast glucose2 4.73 0.57 7.65 2.05
Postprandial 4.91 0.58 8.87 2.09
Before sleep 4.80 0.40 7.45 2.66
Mean 2 4.83 0.45 7.87 1.64
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method of Ward of linkage and Sneath’s test for cluster
significance) are presented (for the control group of 20


















Figure 1: Separation of the control group (the cluster on the left side) from the DTM2 patients by hierarchical cluster analysis using
all input parameters.
Figure 2: Separation of the control group (the cluster on the left side) from the DTM2 patients by PLS-DA approach.
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Four major clusters are formed: the first one includes
all glucose tests (except for HbAc1), the second one –
dominantly the different cholesterol indicators and
enzyme function indicators, the third one – protein and
albumin levels along with HbAc1 and the last one –
blood parameters, anthropometric indicators and BMI,
electrolytes, cholesterol and triglycerides. It could be
assumed that in the control group the clustering of the
tested parameters is distributed mainly with respect to
the body systems and functions involved – enzyme
control and cholesterol deposition, protein exchange,
blood status and metabolic syndrome assessment.
In Figure 4, the same type of dendrogram for the
group of 100 patients with DMT2 is given.
The separation of the 34 clinical parameters (para-
meter “sex” is eliminated from the analysis since
preliminary studies have proven that there is no specific
division between male and female patients) leads to the
formation of the following five clusters:
K1: all glucose tests including the HbAc1 test, which
is considered as one of the most important indicators for
long-term glycemic control – glucose indicator cluster;
K2: (weight, waist, BMI and hip) – anthropometric
indicator cluster;
K3: (thrombocytes, ESR, HDL, LDL, cholesterol,
VLDL and triglycerides) – this cluster indicates the link
between blood quality indicators and cholesterol deposi-
tion indicators – cholesterol cluster;
K4: (ALAT, gamma-glutamyl transferase (GGK),
albumin, total protein, height and K) linkage between
enzyme indicators and protein indicators; the link to K
seems to be interesting – enzyme cluster;
K5: (age, Na, duration, creatinine, uric acid and
CPK) – logical link between age and duration of the
disease as well as between the indicators for the renal
function – renal function cluster.
The clustering of the clinical parameters for the
DMT2 patient group indicates the specificity of the
assessment of the patients with respect to the impact
of the disease on the different organs and systems of the
human body. It is possible to separate a reduced set of
indicators (one or two from each identified cluster) to
perform a rapid assessment of the health status of the
DMT2 patients.
3.1.3 PCA
In order to complete and confirm the results of the
hierarchical clustering of the clinical parameters, PCA
was additionally carried out. It could help for inter-
pretation of the data structure both for the control group




































Figure 3: Hierarchical dendrogram for linkage of clinical parameters for control group.
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and for patients with DMT2. Varimax rotation mode was
used for both data sets (in Table S2 – SI).
Eight latent factors explain over 80% of the total
variance of the system. In general, the significant
grouping of clinical parameters resembles that of
hierarchical clustering – all glucose tests have high
factor loadings in PC1 but HbAc1 does not belong to
this first principal component PC4; the anthropometric
parameters weight, height and hip are correlated (high
factor loadings in PC2). More detailed comparison is not
very correct since in PCA one deals with eight latent
factors since the identified number of clusters in the
hierarchical clustering is four. But PCA gives the
opportunity to reduce the number of variables by
selecting representative variables from each latent factor
(if it is needed to further interpretation).
PC1 (16.6% of explained variance) could be con-
ditionally named “hyperglycemic factor” incorporating
all glucose parameters with high factor loadings.
This most significant “hyperglycemic factor” (16.6%)
described the increased glucose concentrations. It might
reflect the inability of beta-cell to produce sufficient insulin to
maintain normoglycemia, which is the cornerstone for the
DMT2 development [3]. PC2 (11.9% of the total variance)
indicates the close links between the anthropometric para-
meters and could be conditionally named “anthropometric or
obesity factor”. The “obesity” factor (11.9%) emphasized the
important interrelations between visceral fat mass and
carbohydrate dysregulation. Visceral obesity could influence
negatively the glycemic control by increasing insulin
resistance and gluconeogenesis [23]. Therefore, the acquisi-
tion of healthy eating patterns and maintaining of normal
body weight are among the fundamental aspects of the DMT2
treatment plan [24].
High factor loadings for almost all cholesterol
indicators are found in PC3 (7.7% explanation of the
total variance). It is conditionally named “lipid factor”.
The “lipid factor” might explain additional 7.7% of
the group variation. The atherogenic lipid profile of
DMT2 patients is characterized by specific alterations
including hypertriglyceridemia, decreased HDL-choles-
terol levels and a preponderance of smaller denser LDL
cholesterol particles despite the normal LDL cholesterol
blood levels [25]. Insulin resistance might determine not
only the development of hyperglycemia but also the
progress of lipid abnormalities. The increased secretion
of free fatty acid from the adipose tissue as well as their
decreased utilization in the skeletal muscles due to
insulin resistance might enhance their efflux to the liver
leading to impaired triglyceride metabolism [26]. The
correction of lipid abnormalities in diabetic patients
might decrease the risk for macrovascular complications




































Figure 4: Hierarchical dendrogram for linkage of clinical parameters for the group of DMT2 patients.
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and reduce the cardiovascular morbidity and mor-
tality [27].
The PC4 indicates good correlation between throm-
bocytes and ESR (7.4% explained variance) and the
conditional name given is “inflammatory factor”.
The bidirectional interrelations between the DMT2
and inflammation might explain 7.4% of the variations
among diabetic patients and controls. Obesity and insulin
resistance are often associated with an increased expres-
sion of various pro-inflammatory adipocytokines that
might contribute to the maintenance of chronic low-grade
systemic inflammation. The inflammatory response could
facilitate the development of DMT2 by aggravating the
insulin resistance and hyperglycemia, thus creating a
vicious circle [28,29]. Since metabolic dysregulation itself
maintains inflammation, the adequate treatment of the
DMT2, obesity and dyslipidemia might reduce inflamma-
tion by improving the metabolic parameters [30]. The use
of specific anti-inflammatory agents for reduction of
insulin resistance is a matter of further research.
PC5 shows high loadings for age, duration of the
disease (very logical link), uric acid and creatinine
(explained variance of 7.3%). It indicates the impact of
the disease on the kidneys and could be conditionally
named “renal function factor”.
The age and renal function are important determi-
nants of the intragroup variation (7.3%). Ageing is
related to specific difficulties in the diabetes care
because of the pronounced heterogeneity in the health
status of older adults, different patient’s life expectancy,
presence of comorbidities, increased risk for hypogly-
cemia and inability to transfer automatically the results
from anti-diabetic studies conducted on younger pa-
tients to older ones [42]. The care for patients with renal
impairment faces similar problems apart from the
specifically limited therapeutic options [31].
The sixth latent factor explains additional 7.1% of
the total variance. Its conditional name could be “liver
function factor” as it demonstrates correlation between
ALAT and GGT. Additionally, it offers a specific link
between the enzyme indicators with potassium that
could not be explained outside the context of unreported
dietary habits or concomitant treatment.
The liver function is another crucial factor that might
explain additional 7.1% of the total variance.
Hepatocytes are main regulators of the glucose home-
ostasis through the processes of glycogen storage,
glycogenolysis and gluconeogenesis. Thus, hypergly-
cemic states are often found in patients with hepatic
diseases [32]. However, the treatment of diabetes
mellitus in patients with liver disorders might be a
challenge, because of the increased prevalence of
concomitant malnutrition, alcohol abuse, increased risk
of hypoglycemia as well as possible side effect of oral
antidiabetic drugs metabolized in the liver [33].
PC7 (6.5% explanation of the total variance) is a
conditional “protein factor” since it reveals high factor
loadings for total protein and albumin.
The last involved latent component PC8 (5.1%
explanation of the total variance) indicates the specific
role of CPK in the assessment of the health status of the
patients.
The importance of the other two latent factors, such
as protein and CPK levels, is probably associated with an
influence of concomitant conditions and/or medications.
The described traits emphasize on the need of persona-
lized complex care for the individuals at increased risk
for hyperglycemia including a treatment of concomitant
obesity, dyslipidemia and subclinical inflammation
considering their age, renal and liver functions.
Since the PCA is a traditional method for space
reduction, the further goals of the study were important to
select respective variables from the strongly correlated
(high factor loadings) parameters of each identified latent
factor. Considering the important influence of the post-
prandial glucose load, obesity, inflammation, renal and
liver functions for the health status of the patients with
DM2 a restricted set of main indicators was chosen:
postprandial glucose 1, BMI, cholesterol, thrombocytes,
creatinine, uric acid, GGT and K. These indicators
represent each latent factor and count for the role of the
glucose tests, anthropometric indicators, liver function,
renal function, inflammation markers, lipid profile and
electrolytes for effective assessment of the health status of
DMT2 patients.
In Figure 5, the hierarchical dendrogram for all 120
objects of the study (controls and DMT2 patients) is
presented.
It is seen that the separation between both classes of
objects is achieved. The only minor exception is that two
patients with DMT2 are wrongly attributed to the control
group. This is statistically completely acceptable.
One of the general objectives of the present study is
to divide the DMT2 patients into groups of similarity
(clusters) using a discrete number of important para-
meters. This classification could be of use to specific
observation of the health status of the different patients
and, additionally, to support in identifying symptoms of
accompanying DMT2 diseases and complications.
In Figure 6, the hierarchical dendrogram for clus-
tering of 100 DTM2 patients using 8 significant clinical
and anthropometric indicators is shown.
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Four significant clusters are formed. The members of
each cluster are as follows:
Cluster 1 (25 members),
Cluster 2 (31 members),
Cluster 3 (38 members) and
Cluster 4 (6 members).
It could be assumed that each cluster represents
patients with specific health status pattern. In order to
determine the major discriminants for each pattern of
patients, the average values (as standardized values) for
each parameter for each cluster were calculated. Figure 7
represents the results.
Cluster 1 is characterized by highest levels for GGT,
creatinine, uric acid and K. At the same time, it indicates
low BMI, cholesterol and glucose levels. It could be
assumed that the 25 members of this cluster might suffer
from microvascular complications, such as diabetic
nephropathy or they might have concomitant liver or
renal diseases despite the relatively good glycemic
control.
Cluster 2 includes DMT2 patients (quite significant
number) with worsened DMT2 status indicated by the
highest BMI and glucose level (the most significant
discriminants for DMT2). There are no further indications
for accompanying health problems.
Cluster 3 is the pattern of patients (largest number of
members) with improved DMT2 status with no extreme
values of the clinical and anthropometric indicators.
Cluster 4 involves a limited number of patients (only
six). Although having low mean values for BMI, this
pattern of patients shows still high glucose levels as well
as and, additionally, highest cholesterol and thrombocyte
levels, relatively high creatinine and uric acid levels. The
DMT2 status requires significant improvement because of
increased risk of micro- and macrovascular complications
and cardiovascular morbidity and mortality.
The present study succeeded to distribute the DMT2
patients into groups of similarity (patterns or phenotypes)
using a reduced number of commonly tested para-
meters. Using the described statistical approach, four
phenotypes of diabetic patients could be additionally
interpreted.
Phenotype 1 was characterized by parameters
suggesting impaired renal and liver functions. The BMI,
cholesterol and glucose levels were relatively low

















Figure 5: Hierarchical dendrogram for separation between objects of the control group (marked) and DMT2 patients using
eight selected significant parameters.
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Figure 6: Hierarchical dendrogram for clustering of 100 DMT2 patients using 8 variables.
Plot of Means for Each Cluster
 Cluster  1
 Cluster  2
 Cluster  3




















Figure 7: Plot of means (standardized values) for each parameter for each identified cluster.
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glycemic control, malnutrition and the avoidance of
hypoglycemia [31,33]. Therefore, the therapeutic inten-
sity and goals might be less stringent in this category.
Phenotype 2 includes obese diabetic patients with poor
glycemic control but no signs of concomitant health
problems. The therapeutic approach in these patients should
be focused on more intense therapy plan including lifestyle
changes, healthy diet as well as antidiabetic drugs con-
sidering optimal medication adherence. The maintenance of
healthy weight as well as the intensive glycemic control with
the goal of achieving near-normoglycemia is crucial for the
prevention of diabetic complications [34].
Phenotype 3 includes diabetic patients with optimal
laboratory parameters and good control of the hypergly-
cemia. Thus, no therapy changes are needed in this
group of individuals.
Phenotype 4 consists of a limited number of patients
with unfavorable lipid and glucose values as well as
increased uric acid levels despite the lack of obesity.
Probably, these individuals belong to the group of so-
called metabolically obese but normal weight patients,
who are at increased cardiovascular risk due to
increased insulin resistance, hyperglycemia and visceral
fat deposition [35]. Moreover, normal-weight elderly
people with metabolic disturbances have shown a higher
risk of cardiovascular and all-cause mortality in compar-
ison to obese individuals without metabolic disturbances
[36]. Therefore, only the aggressive treatment of lipid
abnormalities as well as the persistent efforts to optimize
glycemic control might preclude the development of
macrovascular complications in that group of patients.
4 Conclusion
The application of exploratory data analysis to classify,
model and interpret clinical data of DMT2 patients has
many aspects – to predict DMT2 by classification
methods among large group of patients, to model the
trajectories of the disease by interpretation of specific
indicators, to identify metabolic and genetic biomarkers
in patients with DMT2 and concomitant cardio-vascular
factors by chemometric approaches, to study diabetic
complications etc. [37–40].
In the present study, an effort is made to determine
significant indicators out of all typical clinical and
anthropometric data for DMT2 patients. The variable
reduction offered (8 out of 35 variables)makes it possible
to achieve the major goals of the study:
• To classify correctly into different class members of the
control group of healthy volunteers from patients
with DMT2.
• To determine by rapid tests, the specific health status
of statistically significant patterns (clusters) of pa-
tients, which allows specific treatment and health care.
• To offer discriminant parameters for each identified
specific pattern of DMT2 patients.
• To create a statistical basis for the personalized
approach in the treatment of patients with DMT2 and
concomitant diseases.
The present study has used intelligent data analysis
to explain the variable traits of diabetic patients
compared to the control group, which could reflect
the differences in the pathophysiological mechanisms
related to the disease. Moreover, different phenotypes
of patients have been identified as in other studies,
which might require distinct therapeutic approach and
goals [41].
In conclusion, further efforts to differentiate distinct
pathophysiological mechanisms and clinical subgroups
through the PCA might contribute to the development of
personalized approach in the management of diabetic
patients.
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